权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms and Duration of Immunity to SARS-CoV-2

SARS-CoV-2 的免疫机制和持续时间

基本信息

批准号：
10854997
负责人：
Scott Dexter Boyd
金额：
$ 299.8万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-23 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10854997
关键词：
2019-nCoV Acute Address African American population Agonist Antibodies Antigen Targeting Attention Award B-Lymphocytes Biopsy Blood COVID-19 COVID-19 diagnosis COVID-19 pandemic COVID-19 patient COVID-19 test Cancer Patient Caucasians Cells Clinical Collaborations Communities Convalescence Data Data Set Dedications Disease Elderly Evaluation Female Hispanic Americans Human Immune Immune response Immune system Immunity Immunologic Memory Immunologics Individual Infection Institution Knowledge Laboratories Longitudinal Studies Mucosal Immune Responses Mucous Membrane Nose Patient Recruitments Patients Peripheral Blood Mononuclear Cell Phenotype Physicians Plasma Plasma Cells Populations at Risk Prognosis Protocols documentation Research Risk Route SARS-CoV-2 immune response SARS-CoV-2 immunity SARS-CoV-2 infection Science Serology Severity of illness Site T cell response T-Lymphocyte Testing Tissue Sample Toll-like receptors Translational Research Translations Vaccination Validation Viral Antigens adaptive immune response adaptive immunity clinical development cohort data sharing immune checkpoint blockade interest male medically underserved medically underserved population member mucosal site novel therapeutic intervention pandemic disease patient population research clinical testing response tool vaccine candidate young adult

项目摘要

OVERALL: SUMMARY We propose the Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) as a member of the SeroNet consortium gathered to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus pandemic that has engulfed the U.S. and the world. Our Center will be based on four scientific pillars:  Deep mechanistic analysis of the adaptive immune responses of COVID-19 patients, spanning serological, B cell and T cell responses,  Analysis of immune responses in the blood as well as mucosal sites,  Comparing immune responses induced by infection to those induced by candidate vaccines, and  Studying medically underserved, underrepresented and at-risk patient populations Within these parameters, we will attempt to determine the factors that result in effective and durable immunity to SARS-CoV-2 infection. We are dedicated to broad collaboration, rapid sharing of data and technical knowledge, nimbleness in responding to the rapidly changing pandemic, and rapid translation of research findings to CLIA Lab clinical testing and development of new therapeutic approaches. We feel these are the best routes forward for addressing gaps in our understanding of the determinants of protective immunity to SARS-CoV-2, and providing useful tools for physicians and patients.

总体:总结